BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27926949)

  • 1. Efficacy and Tolerability of Co-Administering Full µ-Opioid Receptor Agonists with Buprenorphine and Mixed Opioid Agonists.
    Ruan X; Luo J; Kaye AD
    Drug Res (Stuttg); 2017 Mar; 67(3):189-190. PubMed ID: 27926949
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
    Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine maintenance therapy hinders acute pain management in trauma.
    Harrington CJ; Zaydfudim V
    Am Surg; 2010 Apr; 76(4):397-9. PubMed ID: 20420250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.
    Helm S; Trescot AM; Colson J; Sehgal N; Silverman S
    Pain Physician; 2008; 11(2):225-35. PubMed ID: 18354714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
    Zuurmond WW; Meert TF; Noorduin H
    Acta Anaesthesiol Belg; 2002; 53(3):193-201. PubMed ID: 12461829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal buprenorphine in cancer pain and palliative care.
    Sittl R
    Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Office-based opioid dependence treatment.
    Colson J; Helm S; Silverman SM
    Pain Physician; 2012 Jul; 15(3 Suppl):ES231-6. PubMed ID: 22786460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
    Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opiate receptor pharmacology: mixed agonist/antagonist narcotics.
    Hameroff SR
    Contemp Anesth Pract; 1983; 7():27-43. PubMed ID: 6136392
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ; Hanks GW
    Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.
    Seal KH; Maguen S; Bertenthal D; Batki SL; Striebel J; Stein MB; Madden E; Neylan TC
    J Clin Psychiatry; 2016 Sep; 77(9):1182-1188. PubMed ID: 27035058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.
    Janas A; Folwarczna J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):175-185. PubMed ID: 27896372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.